HEK 293

The Human Embryonic Kidney 293 (HEK293) cell line stands as one of the most widely adopted and thoroughly validated mammalian expression systems in modern biomedical research. Originally established in 1973 by Alex van der Eb and Frank Graham at Leiden University through stable transfection of normal human fetal kidney cells with sheared adenovirus type 5 DNA, HEK293 cells have since become an indispensable platform across academic, biotechnology, and biopharmaceutical settings - second only to HeLa cells in global research utilization.

A defining strength of HEK293 cells lies in their exceptional transfection efficiency, readily accepting foreign genetic material via a broad spectrum of chemical, physical, and viral delivery methods, significantly reducing experimental turnaround compared to alternative cell lines such as CHO. As a human-origin cell line, HEK293 cells are uniquely capable of performing complex human-like post-translational modifications (PTMs) - including glycosylation, phosphorylation, and γ-carboxylation - ensuring that recombinant proteins are produced with authentic biological activity and structural fidelity that non-human systems fundamentally cannot replicate.

HEK293 cells exhibit rapid proliferation, robust adaptability to both adherent and suspension culture formats, and proven compatibility with serum-free media, enabling scalable protein production under GMP-aligned conditions. Their consistent, batch-to-batch reproducibility makes them an ideal model for receptor signaling studies, viral vector manufacturing, drug screening, toxicology assessment, and the production of therapeutic proteins.

Furthermore, the versatile HEK293 cell family - including the widely used HEK293T variant expressing the SV40 Large T antigen for enhanced episomal replication - offers researchers flexible, fit-for-purpose solutions across transient and stable expression paradigms.